This study is testing a new medicine called **TAB004**, which is a type of medicine known as a **monoclonal antibody** (a special protein made in labs to target and fight specific parts of cells) to see if it is safe and how it behaves in the body. It’s for people with advanced cancers that have not been cured by other treatments. The study will look at TAB004 alone and with another medicine called **toripalimab**. **BTLA** is a part of the immune system that this medicine targets, while **PD-1** is another immune part targeted by toripalimab.

Key Points:

• The study could last up to 2 years with visits every 21 days.
• Participants will receive TAB004 alone or with toripalimab through an **IV infusion** (medicine given through a vein).
• Safety checks include health exams, blood tests, and watching for side effects.

Participants must be adults with certain types of cancers and meet health requirements. Risks may include immune system reactions or other side effects. Compensation is not mentioned, and it's important to discuss with the study team about participation.